Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
2.020
+0.060 (3.06%)
Feb 18, 2026, 12:20 PM EST - Market open
Traws Pharma Revenue
Traws Pharma had revenue of $2.85M in the twelve months ending September 30, 2025, up 1,159.29% year-over-year. In the year 2024, Traws Pharma had annual revenue of $226.00K.
Revenue (ttm)
$2.85M
Revenue Growth
+1,159.29%
P/S Ratio
4.59
Revenue / Employee
$406,571
Employees
7
Market Cap
16.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 226.00K | - | - |
| Dec 31, 2023 | 226.00K | - | - |
| Dec 31, 2022 | 226.00K | - | - |
| Dec 31, 2021 | 226.00K | -5.00K | -2.16% |
| Dec 31, 2020 | 231.00K | -1.95M | -89.42% |
| Dec 31, 2019 | 2.18M | 955.00K | 77.77% |
| Dec 31, 2018 | 1.23M | 441.00K | 56.04% |
| Dec 31, 2017 | 787.00K | -4.76M | -85.81% |
| Dec 31, 2016 | 5.55M | -5.91M | -51.59% |
| Dec 31, 2015 | 11.46M | 10.66M | 1,332.00% |
| Dec 31, 2014 | 800.00K | -3.95M | -83.17% |
| Dec 31, 2013 | 4.75M | -41.44M | -89.71% |
| Dec 31, 2012 | 46.19M | 44.70M | 3,006.25% |
| Dec 31, 2011 | 1.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTRAW News
- 5 weeks ago - Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients - GlobeNewsWire
- 3 months ago - ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials - PRNewsWire
- 4 months ago - Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. - PRNewsWire
- 4 months ago - Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 - GlobeNewsWire
- 6 months ago - Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 - GlobeNewsWire
- 6 months ago - Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Traws Pharma Reports Second Quarter 2025 Results and Business Highlights - GlobeNewsWire
- 6 months ago - Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - GlobeNewsWire